BeiGene Approved to Launch Brukinsa® for 3rd B-Cell Cancer Indication

Beijing 's BeiGene was conditionally approved to launch Brukinsa® (zanubrutinib) in China for adult patients with Waldenström’s macroglobulinemia (WM). In WM patients who had received at least one previous therapy, the single-arm pivotal China Phase II trial of zanubrutinib found 72% of patients experienced a major response rate at a median follow-up time of 15 months. Zanubrutinib is now approved for three B-cell indications in China . More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //